|Awarded On||August 18, 2021|
|Title||Tunable epigenetic remodeling to modulate CAR T-cell based immunotherapy|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Texas A&M University System Health Science Center|
|Principal Investigator/Program Director||Yubin Zhou|
|Cancer Sites||Leukemia, Lymphoma, Skin|
*Pending contract negotiation
This project is tightly aligned with the CPRIT mission to find a cure for cancer in order to save lives and prevent cancer. The goal of the proposed work is to engineer smart therapeutic T cells to advance precision medicine by delivering durable and controllable cell-based immunotherapy against cancer. Over the past five years, chimeric antigen receptor (CAR) T-cell based immunotherapy, also regarded as “living drugs” in the body, has achieved miraculous outcomes in certain patients with lymphoma and leukemia. Nonetheless, CAR T-cell therapy still faces challenges, partially because of severe side effects and its inability to last long-term therapeutic effects in some cancer patients. B...